Health-related quality of life in Japanese men with localized prostate cancer: Assessment with the SF-8
Health-related quality of life in Japanese men with localized prostate cancer: Assessment with the SF-8
复制标题
DOI：
10.1111/j.1442-2042.2008.02046.x
复制
发表时间：
2008-06-01
影响因子：
2.6
通讯作者：
Kakehi, Yoshiyuki
中科院分区：
文献类型：
--
作者：
Sugimoto, Mikio;Takegami, Misa;Kakehi, Yoshiyuki
目的：研究日本早期前列腺癌患者的健康相关生活质量(HRQOL)。方法：对457例前列腺癌患者采用前列腺癌根治术、外照射、近距离放射治疗、去雄激素治疗、警惕等待或联合治疗进行横断面分析。用日本版的SF-8问卷测量一般的HRQOL，用日本版的扩展前列腺癌指数综合评定量表评估特定疾病的HRQOL。结果：外照射组的身体健康综合评分(PCS)显著低于前列腺癌根治术和近距离放疗组(P<；0.05)。在分析治疗后PCS和精神健康部分总分(MCS)随时间变化的分析中，根治性前列腺切除术组的得分随时间的变化更高。在雄激素剥夺治疗后，PCS中没有发现明显的时间变化。结论：SF-8与扩展前列腺癌综合指数相结合在日本局部前列腺癌患者的HRQOL评估中是一种有用的工具。
Objectives: To evaluate health related quality of life (HRQOL) using the Medical Outcomes Study 8-items Short Form Health Survey (SF-8) questionnaire in Japanese patients with early prostate cancer.Methods: A cross-sectional analysis was done in 457 patients with prostate cancer treated with radical prostatectomy, external beam radiotherapy, brachytherapy, androgen deprivation therapy, and watchful waiting or a combination these therapies. General HRQOL was measured using the Japanese version of the SF-8 questionnaire and disease-specific HRQOL was assessed using the Japanese version of the Extended Prostate Cancer Index Composite.Results: The external beam radiotherapy group reported significantly lower values for the physical health component summary score (PCS) in comparison to the radical prostatectomy and brachytherapy groups (P < 0.05). In the analysis of both the PCS and the mental health component summary score (MCS) over time after treatment, higher scores with time were found in the radical prostatectomy group. No significant change over time after androgen deprivation therapy in the PCS was found. In contrast, the MCS was found to deteriorate in the early period, showing a significant increase over time.Conclusions: SF-8 in combination with the Extended Prostate Cancer Index Composite has shown to be a helpful tool in the HRQOL assessment of Japanese patients treated for localized prostate cancer.